Álvaro Gimeno Díaz de Atauri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Álvaro Gimeno Díaz de Atauri has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Mirella Gaboli
Pediatric Pulmonology and Allergology Department, Virgen del Rocio University Hospital, Biomedicine Institute of Seville (IBIS), Seville, Spain
3 shared publications - Verónica Sanz-Santiago
Department of Paediatric Pulmonology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
3 shared publications - Alejandro López-Neyra
Department of Paediatric Pulmonology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
2 shared publications - Alfredo Valenzuela Soria
Pediatric Pulmonology Unit Hospital Universitario Virgen de las Nieves Granada Spain
2 shared publications - Andrea Freixa
Department of Pediatrics, Obstetrics and Gynecology and Preventive Medicine and Public Health, University Autònoma de Barcelona, Bellaterra, Spain; Pediatric Cardiology Service, Vall Hebron University Hospital, Barcelona, Spain; Pediatric Cardiology Service, Royal Brompton Hospital, London, United Kingdom
2 shared publications - Angel Mazon
Unit of Paediatric Allergy and Pneumology Hospital La Fe. Research Institute La Fe Valencia Spain
2 shared publications
Latest Publications
- Open Access
- 16 July 2025
- Published by Elsevier in Anales de Pediatría
- Vol. 103 (4)
Lectura crítica (I): Fundamentos, herramientas y su aplicación en artículos científicos sobre pronóstico y efectos perjudiciales
- 16 July 2025
- Published by Elsevier in Anales de Pediatría
- Vol. 103 (4)
Open AccessLectura crítica (I): Fundamentos, herramientas y su aplicación en artículos científicos sobre pronóstico y efectos perjudiciales
- 8 April 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (4) , e13942
Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain
Background: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.Methods: A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.Results: The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.Conclusion: The use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.
- 8 April 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (4) , e13942
Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain
Background: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.Methods: A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.Results: The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.Conclusion: The use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.
- 1 January 2022
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 58 (1) , 22-29
Incidence and Prevalence of Children's Diffuse Lung Disease in Spain
- 1 January 2022
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 58 (1) , 22-29
Incidence and Prevalence of Children's Diffuse Lung Disease in Spain
- 22 February 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 32 (5) , 980-991
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma
Background: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow‐up and/or number of patients included were limited. We aim to describe the long‐term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real‐life cohort reported to date.Methods: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow‐up. The primary outcome was the evolution of the annual number of moderate‐to‐severe exacerbations compared with the baseline period.Results: Of the 484 patients included, 101 (20.9%) reached 6 years of treatment. The mean ± standard deviation number of exacerbations decreased during the first year of treatment (7.9 ± 6.6 to 1.1 ± 2.0, P < .001) and remained likewise for up to 6 years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution.Conclusion: In this large, long‐term, observational study, moderate‐to‐severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long‐term treatment in pediatric patients with severe persistent allergic asthma.
- 22 February 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 32 (5) , 980-991
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma
Background: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow‐up and/or number of patients included were limited. We aim to describe the long‐term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real‐life cohort reported to date.Methods: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow‐up. The primary outcome was the evolution of the annual number of moderate‐to‐severe exacerbations compared with the baseline period.Results: Of the 484 patients included, 101 (20.9%) reached 6 years of treatment. The mean ± standard deviation number of exacerbations decreased during the first year of treatment (7.9 ± 6.6 to 1.1 ± 2.0, P < .001) and remained likewise for up to 6 years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution.Conclusion: In this large, long‐term, observational study, moderate‐to‐severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long‐term treatment in pediatric patients with severe persistent allergic asthma.